GlassScriptPhysician profile
Gordon H Robinson
NPI 1245342161
$5,813.18
in general payments reported to CMS, 2019-2025
40 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $876 · 2021: $929 · 2022: $568 · 2023: $441 · 2024: $647 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $712.31 | 2019-2024 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $477.25 | 2019 | |
| Abbvie INC. | $431.67 | 2021-2024 | Vraylar |
| Allergan, INC. | $412.43 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $383.55 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $292.41 | 2019-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $224.02 | 2019-2024 | Trintellix |
| Alkermes, INC. | $222.86 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $215.53 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.76 | 2020-2025 | Caplyta |
| Bausch Health US, LLC | $170.37 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $161.26 | 2019-2022 | |
| Neos Therapeutics, LP | $157.43 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $151.95 | 2024-2025 | Cobenfy |
| Corium, LLC | $150.48 | 2022-2025 | Azstarys |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.